Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Inclusion Criteria

• •Patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days.
• •ECOG performance status 0, 1 or 2
• •Age \> 18 years
• •Adequate kidney and hepatic function
• •Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea.
• •Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion.